Printable Format65-4109. Substances included in schedule III. (a) The controlled substances listed in this section are included in schedule III and the number set forth opposite each drug or substance is the DEA controlled substances code which has been assigned to it.
(b) Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:
|
(1) |
Any compound, mixture or preparation containing: |
|
|
|
(A) |
Amobarbital |
2126 |
|
|
(B) |
Secobarbital |
2316 |
|
|
(C) |
Pentobarbital
|
2271 |
|
|
|
|||
|
(2) |
Any suppository dosage form containing: |
|
|
|
(A) |
Amobarbital |
2126 |
|
|
(B) |
Secobarbital |
2316 |
|
|
(C) |
Pentobarbital
|
2271 |
|
|
|
|||
|
(3) |
Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules |
2100 |
|
|
(4) |
Chlorhexadol |
2510 |
|
|
(5) |
Lysergic acid |
7300 |
|
|
(6) |
Lysergic acid amide |
7310 |
|
|
(7) |
Methyprylon |
2575 |
|
|
(8) |
Sulfondiethylmethane |
2600 |
|
|
(9) |
Sulfonethylmethane |
2605 |
|
|
(10) |
Sulfonmethane |
2610 |
|
|
(11) |
Tiletamine and zolazepam or any salt thereof
|
7295 |
|
|
|
|||
|
(12) |
Ketamine, its salts, isomers, and salts of isomers Some other names for ketamine: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone |
7285 |
|
|
|
|||
|
(13) |
Gamma hydroxybutyric acid, any salt, hydroxybutyric compound, derivative or preparation of gamma hydroxybutyric acid contained in a drug product for which an application has been approved under section 505 of the federal food, drug and cosmetic act |
|
|
|
(14) |
Embutramide |
2020 |
|
|
(15) |
Perampanel, its salts, isomers, and salts of isomers Some other names for perampanel: 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2 dihydropyridin-3-yl) benzonitrile |
2261 |
|
|
|
|||
|
(c) |
Nalorphine |
9400 |
(d) Any material, compound, mixture or preparation containing any of the following narcotic drugs or any salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
|
(1) |
Not more than 1.8 grams of codeine or any of its salts per 100 milliliters or not more than 90 milligrams per dosage unit with an equal or greater quantity of an isoquinoline alkaloid of opium |
9803 |
|
|
(2) |
not more than 1.8 grams of codeine or any of its salts per 100 milliliters or not more than 90 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
9804 |
|
|
(3) |
not more than 1.8 grams of dihydrocodeine or any of its salts per 100 milliliters or not more than 90 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
9807 |
|
|
(4) |
not more than 300 milligrams of ethylmorphine or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
9808 |
|
|
(5) |
not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
9809 |
|
|
(6) |
not more than 50 milligrams of morphine or any of its salts per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
9810 |
|
|
(7) |
any material, compound, mixture or preparation containing any of the following narcotic drugs or their salts, as set forth below: |
|
|
|
(A) |
Buprenorphine |
9064 |
|
(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:
|
(1) |
Those compounds, mixtures or preparations in dosage unit form containing any stimulant substance listed in schedule II, which compounds, mixtures or preparations were listed on August 25, 1971, as excepted compounds under section 308.32 of title 21 of the code of federal regulations, and any other drug of the quantitive composition shown in that list for those drugs or which is the same, except that it contains a lesser quantity of controlled substances |
1405 |
|
(2) |
Benzphetamine |
1228 |
|
(3) |
Chlorphentermine |
1645 |
|
(4) |
Chlortermine |
1647 |
|
(5) |
Phendimetrazine |
1615 |
|
(f) |
Anabolic steroids |
4000 |
"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promotes muscle growth, and includes:
|
(1) |
3β,17-dihydroxy-5a-androstane |
|
|
(2) |
3α,17β-dihydroxy-5a-androstane |
|
|
(3) |
5a-androstan-3,17-dione |
|
|
(4) |
1-androstenediol (3β,17β-dihydroxy-5α-androst-1-ene) |
|
|
(5) |
1-androstenediol (3α,17β-dihydroxy-5α-androst-1-ene) |
|
|
(6) |
4-androstenediol (3β,17β-dihydroxy-androst-4-ene) |
|
|
(7) |
5-androstenediol (3β,17β-dihydroxy-androst-5-ene) |
|
|
(8) |
1-androstenedione ([5α]-androst-1-en-3,17-dione) |
|
|
(9) |
4-androstenedione (androst-4-en-3,17-dione) |
|
|
(10) |
5-androstenedione (androst-5-en-3,17-dione) |
|
|
(11) |
bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one) |
|
|
(12) |
boldenone (17β-hydroxyandrost-1,4-diene-3-one) |
|
|
(13) |
boldione (androsta-1,4-diene-3,17-dione) |
|
|
(14) |
calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one) |
|
|
(15) |
clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one) |
|
|
(16) |
dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-one) |
|
|
(17) |
desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol) (also known as "madol") |
|
|
(18) |
Δ1-dihydrotestosterone (17β-hydroxy-5α-androst-1-en-3-one) (also known as "1-testosterone") |
|
|
(19) |
4-dihydrotestosterone (17β-hydroxy-androstan-3-one) |
|
|
(20) |
drostanolone (17β-hydroxy-2α-methyl-5α-androstan-3-one) |
|
|
(21) |
ethylestrenol (17α-ethyl-17β-hydroxyestr-4-ene) |
|
|
(22) |
fluoxymesterone (9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one) |
|
|
(23) |
formebolone (2-formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one) |
|
|
(24) |
furazabol (17α-methyl-17β-hydroxyandrostano[2,3-c]-furazan) |
|
|
(25) |
13β-ethyl-17β-hydroxygon-4-en-3-one |
|
|
(26) |
4-hydroxytestosterone (4,17β-dihydroxy-androst-4-en-3-one) |
|
|
(27) |
4-hydroxy-19-nortestosterone (4,17β-dihydroxy-estr-4-en-3-one) |
|
|
(28) |
mestanolone (17α-methyl-17β-hydroxy-5-androstan-3-one) |
|
|
(29) |
mesterolone (1α-methyl-17β-hydroxy-[5α]-androstan-3-one) |
|
|
(30) |
methandienone (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one) |
|
|
(31) |
methandriol (17α-methyl-3β,17β-dihydroxyandrost-5-ene) |
|
|
(32) |
methasterone (2α,17α-dimethyl-5α-androstan-17β-ol-3-one) |
|
|
(33) |
methenolone (1-methyl-17β-hydroxy-5α-androst-1-en-3-one) |
|
|
(34) |
17α-methyl-3β,17β-dihydroxy-5a-androstane |
|
|
(35) |
17α-methyl-3α,17β-dihydroxy-5a-androstane |
|
|
(36) |
17α-methyl-3β,17β-dihydroxyandrost-4-ene |
|
|
(37) |
17α-methyl-4-hydroxynandrolone (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one) |
|
|
(38) |
methyldienolone (17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one) |
|
|
(39) |
methyltrienolone (17α-methyl-17β-hydroxyestra-4,9,11-trien-3-one) |
|
|
(40) |
methyltestosterone (17α-methyl-17β-hydroxyandrost-4-en-3-one) |
|
|
(41) |
mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en-3-one) |
|
|
(42) |
17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (also known as "17-α-methyl-1-testosterone") |
|
|
(43) |
nandrolone (17β-hydroxyestr-4-en-3-one) |
|
|
(44) |
19-nor-4-androstenediol (3β, 17β-dihydroxyestr-4-ene) |
|
|
(45) |
19-nor-4-androstenediol (3α, 17β-dihydroxyestr-4-ene) |
|
|
(46) |
19-nor-5-androstenediol (3β, 17β-dihydroxyestr-5-ene) |
|
|
(47) |
19-nor-5-androstenediol (3α, 17β-dihydroxyestr-5-ene) |
|
|
(48) |
19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione) |
|
|
(49) |
19-nor-4-androstenedione (estr-4-en-3,17-dione) |
|
|
(50) |
19-nor-5-androstenedione (estr-5-en-3,17-dione) |
|
|
(51) |
norbolethone (13β, 17α-diethyl-17β-hydroxygon-4-en-3-one) |
|
|
(52) |
norclostebol (4-chloro-17β-hydroxyestr-4-en-3-one) |
|
|
(53) |
norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-3-one) |
|
|
(54) |
normethandrolone (17α-methyl-17β-hydroxyestr-4-en-3-one) |
|
|
(55) |
oxandrolone (17α-methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one) |
|
|
(56) |
oxymesterone (17α-methyl-4,17β-dihydroxyandrost-4-en-3-one) |
|
|
(57) |
oxymetholone (17α-methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-one) |
|
|
(58) |
prostanozol (17β-hydroxy-5α-androstano[3,2-c]pyrazole) |
|
|
(59) |
stanozolol (17α-methyl-17β-hydroxy-[5α]-androst-2-eno[3,2-c]-pyrazole) |
|
|
(60) |
stenbolone (17β-hydroxy-2-methyl-[5α]-androst-1-en-3-one) |
|
|
(61) |
testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone) |
|
|
(62) |
testosterone (17β-hydroxyandrost-4-en-3-one) |
|
|
(63) |
tetrahydrogestrinone (13β, 17α-diethyl-17β-hydroxygon-4,9,11-trien-3-one) |
|
|
(64) |
trenbolone (17β-hydroxyestr-4,9,11-trien-3-one) |
|
|
(65) |
any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. |
|
|
|
(A) |
Except as provided in (B), such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the United States' secretary of health and human services for such administration. |
|
|
(B) |
If any person prescribes, dispenses or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this subsection (f). |
(g) Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substance, its salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:
|
(1) |
Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product |
7369 |
|
Some other names for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro -6-6-9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-0l, or (-)-delta-9-(trans)-tetrahydrocannabinol. |
|
(h) The board may except by rule any compound, mixture or preparation containing any stimulant or depressant substance listed in subsection (b) from the application of all or any part of this act if the compound, mixture or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system and if the admixtures are included therein in combinations, quantity, proportion or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.
History: L. 1972, ch. 234, § 9; L. 1974, ch. 258, § 4; L. 1978, ch. 257, § 2; L. 1982, ch. 269, § 4; L. 1985, ch. 220, § 3; L. 1989, ch. 200, § 3; L. 1991, ch. 199, § 3; L. 1992, ch. 174, § 3; L. 2000, ch. 108, § 3; L. 2001, ch. 171, § 4; L. 2011, ch. 83, § 5; L. 2014, ch. 79, § 2; L. 2015, ch. 27, § 3; L. 2016, ch. 95, § 3; L. 2018, ch. 101, § 3; May 24.
Revisor's Note:
Section was also amended by L. 2011, ch. 10, § 3, but that version was repealed by L. 2011, ch. 83, § 9.
Section was not amended in the 2016 session.
CASE ANNOTATIONS
1. Appeal from conviction for sale of narcotic drugs; no error in overruling motions for acquittal, continuance or for new trial. State v. Holt, 221 K. 696, 561 P.2d 435.
2. Possession of the narcotic in Lortab is a felony under 65-4160. State v. Surowski, 42 K.A.2d 304, 212 P.3d 229 (2009).